Skip Navigation



eCAM Advance Access published online on September 14, 2009

eCAM, doi:10.1093/ecam/nep140
This Article
Right arrow Full Text Freely available
Right arrow Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Chiou, W.-F.
Right arrow Articles by Wei, B.-L.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chiou, W.-F.
Right arrow Articles by Wei, B.-L.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


© The Author(s) 2009. Published by Oxford University Press.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/2.5/uk/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

3,4-Di-O-Caffeoylquinic Acid Inhibits Angiotensin-II-induced Vascular Smooth Muscle Cell Proliferation and Migration by Downregulating the JNK and PI3K/Akt Signaling Pathways

Wen-Fei Chiou1,2,3, Chien-Chih Chen1 and Bai-Luh Wei2

1National Research Institute of Chinese Medicine, Taipei, 2Institute of Life Science, Collage of Science and Engineering, National Taitung University, Taitung and 3Institute of Traditional Medicine, School of Medicine, National Yang-Ming University, Taipei, Taiwan

We previously reported 3,4-di-O-caffeoylquinic acid (CQC) protected vascular endothelial cells against oxidative stress and restored impaired endothelium-dependent vasodilatation. Here, we further investigated its anti-atherosclerotic effect against angiotensin II (Ang II) evoked proliferation and migration of cultured rat vascular smooth muscle cells (rVSMC). The results showed CQC (1–20 µM) clearly inhibited Ang-II-stimulated BrdU incorporation and cell migration of rVSMC in a concentration-dependent manner but without significant cytotoxicity. Western blot analysis revealed Ang II increased the phosphorylation levels of Akt and mitogen-activated protein kinases (MAPKs;p38, ERK1/2 and JNK) in rVSMC. In the presence of phosphatidylinositol 3-kinase (PI3K) inhibitor wortmannin and three individual MAPK inhibitors SB203580, PD98059 and SP600125, both Ang-II-induced cell proliferation and migration were significantly attenuated, although to differing extents, suggesting the PI3K and MAPK signal pathways all participated in regulating rVSMC proliferation and migration. Also, the CQC pretreatment markedly suppressed Ang-II-induced phosphorylation of Akt and JNK rather than ERK1/2, although it failed to affect p38 phosphorylation. In conclusion, our data demonstrate CQC may act by down-regulating Akt, JNK and part of the ERK1/2 pathways to inhibit Ang-II-induced rVSMC proliferation and migration. The anti-atherosclerotic effect of CQC is achieved either by endothelial cells protection or by VSMC proliferation/migration inhibition, suggesting this compound may be useful in preventing vascular diseases.

Keywords: Akt – 3,4-di-O-caffeoylquinic acid (CQC) – MAPK – migration – proliferation – vascular smooth muscle cell


For reprints and all correspondence: Wen-Fei Chiou, Division of Basic Chinese Medical Research, National Research Institute of Chinese Medicine, No. 155-1, Sec. 2, Li-Nung St., Shipai, Taipei 112, Taiwan, ROC. Tel: +886-2-2820199 ext.: 4481; Fax: +886-2-28264343; E-mail: wfchiou{at}cma23.nricm.edu.tw

Received May 14, 2009; accepted August 17, 2009


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.